Elisabetta Rosi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elisabetta Rosi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Salvicchi
Thoracic Surgery Unit, Careggi University Hospital, 50134 Florence, Italy
1 shared publication Alessandra Bindi
Department of Radiology, Emergency Radiology AOU Careggi, FIRENZE, Italy
1 shared publication- Alessandro Gonfiotti
Thoracic Surgery Unit, Careggi University Hospital, 50134 Florence, Italy
1 shared publication - Andrea Dell’amore
Department of Cardiac, Thoracic, Vascular Sciences and Public Health University of Padua Padua Italy
1 shared publication Arianna Belli
Respiratory Unit, Department of Experimental and Clinical Medicine, Careggi University Hospital, FIRENZE, Italy
1 shared publicationBarbara Fricelli
Respiratory Unit, Department of Experimental and Clinical Medicine, Careggi University Hospital, FIRENZE, Italy
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3029
Integrated management of patients with ILD and cancer: the experience of an Italian center
Background: Interstitial lung diseases (ILDs) are a risk factor for lung cancer and occur in approximately 6-15% of lung cancer patients at diagnosis. Lung cancer negatively impacts survival in patients with ILD, and complications related to cancer treatment result in death in a significant number of cases. Drug therapy for advanced cancer has undergone significant changes in recent years with the advent of new targeted therapies, which have led to a significant increase in pulmonary toxicity. Objective: Due to the increasing number of patients with ILD and cancer who are referred to our respiratory center, we have created a dedicated outpatient activity with the collaboration of pulmonologists, oncologists, thoracic surgeons, radiotherapists Methods: We describe the results of 2 years of activity of the outpatient clinic for patients affected by ILD-associated cancer at the Respiratory Clinic of Careggi University Hospital, Florence, Italy. Results: We evaluated 140 patients (M/F: 72/68) affected by ILD and cancer from January 2024 to December 2025. We observed three different scenarios: 1. Patient with ILD who develops cancer (n: 35, 25%) 2. Patient diagnosed with cancer concurrently with ILD (n: 42, 30%) 3. Patient with cancer who develops ILD (also due to toxicity of anticancer therapy) (n: 63, 45%). The patients underwent collegially agreed treatments and subsequently re-evaluated Conclusions: Integrated management of patients with ILD and cancer in a dedicated setting may result in early identification of fibrosing ILD, appropriate prescription of antifibrotic therapies (which reduce the risk of acute exacerbation) and timely management of pulmonary toxicity due to cancer treatments.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3029
Integrated management of patients with ILD and cancer: the experience of an Italian center
Background: Interstitial lung diseases (ILDs) are a risk factor for lung cancer and occur in approximately 6-15% of lung cancer patients at diagnosis. Lung cancer negatively impacts survival in patients with ILD, and complications related to cancer treatment result in death in a significant number of cases. Drug therapy for advanced cancer has undergone significant changes in recent years with the advent of new targeted therapies, which have led to a significant increase in pulmonary toxicity. Objective: Due to the increasing number of patients with ILD and cancer who are referred to our respiratory center, we have created a dedicated outpatient activity with the collaboration of pulmonologists, oncologists, thoracic surgeons, radiotherapists Methods: We describe the results of 2 years of activity of the outpatient clinic for patients affected by ILD-associated cancer at the Respiratory Clinic of Careggi University Hospital, Florence, Italy. Results: We evaluated 140 patients (M/F: 72/68) affected by ILD and cancer from January 2024 to December 2025. We observed three different scenarios: 1. Patient with ILD who develops cancer (n: 35, 25%) 2. Patient diagnosed with cancer concurrently with ILD (n: 42, 30%) 3. Patient with cancer who develops ILD (also due to toxicity of anticancer therapy) (n: 63, 45%). The patients underwent collegially agreed treatments and subsequently re-evaluated Conclusions: Integrated management of patients with ILD and cancer in a dedicated setting may result in early identification of fibrosing ILD, appropriate prescription of antifibrotic therapies (which reduce the risk of acute exacerbation) and timely management of pulmonary toxicity due to cancer treatments.
- Open Access
Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
Background: The surgical treatment of concomitant lung cancer in patients with idiopathic pulmonary fibrosis is challenging due to the risk of life-threatening complications such as acute exacerbation development in the perioperative period. Few studies have investigated the role of anti-fibrotic drugs in this setting. The aim of this multicenter retrospective study was to evaluate the incidence of acute exacerbation, according to Collard, after lung resection in patients affected by concomitant idiopathic pulmonary fibrosis and lung cancer who were or were not on antifibrotic treatment. Secondary outcomes included: 30 and 90-day mortality and an estimation of overall and disease-free survival. Material and Methods: The study population consisted of patients affected by idiopathic pulmonary fibrosis who received curative-intent lung surgery in three Italian academic centers between 2015 and 2022. Patients were divided into two groups based on whether they were on perioperative treatment with anti-fibrotic drugs (chronical or prophylactic use) or not. To define predictors of acute exacerbation, univariate and multivariable exact logistic regression analysis were performed. The Kaplan–Meier method with log-rank test was used to estimate survival. Results: During the study period, n = 55 patients underwent lung resection for lung cancer, including 29 patients who were treated with antifibrotic agents. Although the sample size was small and few events were studied, the incidence of acute exacerbation was significantly lower among patient on anti-fibrotic therapy (3.4% vs. 23.1%, p = 0.044); in addition, anti-fibrotic treatment was the strong factor preventing acute exacerbation at the multivariable analysis (OR 0.089, p = 0.038). Post-operative 30- and 90-day mortality rates were not significantly lower in the anti-fibrotic treatment group (0% and 0% vs. 7.7% and 11.5%, p = 0.21 and p = 0.099, respectively). Overall and disease-free survival rates were similar. Conclusions: Considering the limitations of this retrospective study with a small sample size, anti-fibrotic perioperative treatment was associated with reduced incidence of acute exacerbation. Based on these real-world data, this pathway could be proposed as a prophylactic treatment in patients with concomitant idiopathic pulmonary fibrosis and cancer undergoing lung resection.
Open AccessPerioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery
Background: The surgical treatment of concomitant lung cancer in patients with idiopathic pulmonary fibrosis is challenging due to the risk of life-threatening complications such as acute exacerbation development in the perioperative period. Few studies have investigated the role of anti-fibrotic drugs in this setting. The aim of this multicenter retrospective study was to evaluate the incidence of acute exacerbation, according to Collard, after lung resection in patients affected by concomitant idiopathic pulmonary fibrosis and lung cancer who were or were not on antifibrotic treatment. Secondary outcomes included: 30 and 90-day mortality and an estimation of overall and disease-free survival. Material and Methods: The study population consisted of patients affected by idiopathic pulmonary fibrosis who received curative-intent lung surgery in three Italian academic centers between 2015 and 2022. Patients were divided into two groups based on whether they were on perioperative treatment with anti-fibrotic drugs (chronical or prophylactic use) or not. To define predictors of acute exacerbation, univariate and multivariable exact logistic regression analysis were performed. The Kaplan–Meier method with log-rank test was used to estimate survival. Results: During the study period, n = 55 patients underwent lung resection for lung cancer, including 29 patients who were treated with antifibrotic agents. Although the sample size was small and few events were studied, the incidence of acute exacerbation was significantly lower among patient on anti-fibrotic therapy (3.4% vs. 23.1%, p = 0.044); in addition, anti-fibrotic treatment was the strong factor preventing acute exacerbation at the multivariable analysis (OR 0.089, p = 0.038). Post-operative 30- and 90-day mortality rates were not significantly lower in the anti-fibrotic treatment group (0% and 0% vs. 7.7% and 11.5%, p = 0.21 and p = 0.099, respectively). Overall and disease-free survival rates were similar. Conclusions: Considering the limitations of this retrospective study with a small sample size, anti-fibrotic perioperative treatment was associated with reduced incidence of acute exacerbation. Based on these real-world data, this pathway could be proposed as a prophylactic treatment in patients with concomitant idiopathic pulmonary fibrosis and cancer undergoing lung resection.